Kemmerer J M, Rubio F A, McClain R M, Koechlin B A
J Pharm Sci. 1979 Oct;68(10):1274-80. doi: 10.1002/jps.2600681021.
A procedure was developed for the separation and selective quantitative determination of the (S)(+)- and (R)(-)-enantiomers of the racemic anti-inflammatory drug carprofen as their diastereomeric l-(-)-alpha-methylbenzylamides. These derivatives are obtained in equivalent yields by reacint purified 14C-carprofen from biological specimens with l-(-)-alpha-methylbenzylamine via the 1,1'-carbonyldiimidazole intermediate, followed by extraction and differential radiometric quantitation of the TLC-separated diastereomers. In the rat, the (R)(-)-carprofen enantiomer was eliminated from blood and secreted in the bile as the ester glucuronide at a rate approximately twice that of the (S)-(+)-enantiomer, resulting in the accumulation of the pharmacologically more active (S)(+)-enantiomer in the rat blood. Evidence for an additional process favoring the elimination of the (R)(-)-enantiomer in the rat was derived from pharmacokinetic data evaluation.
已开发出一种程序,用于分离和选择性定量测定外消旋抗炎药卡洛芬的(S)(+)-和(R)(-)-对映体,以其非对映体L-(-)-α-甲基苄基酰胺形式存在。通过将生物样品中纯化的14C-卡洛芬与L-(-)-α-甲基苄胺经1,1'-羰基二咪唑中间体反应,以等量产率获得这些衍生物,随后对TLC分离的非对映体进行萃取和差示放射定量分析。在大鼠中,(R)(-)-卡洛芬对映体从血液中消除并以酯葡糖醛酸苷形式分泌到胆汁中的速率约为(S)(+)-对映体的两倍,导致药理活性更高的(S)(+)-对映体在大鼠血液中蓄积。支持大鼠体内存在另一个有利于消除(R)(-)-对映体的过程的证据来自药代动力学数据评估。